Price
No data yet.
Social Signal Score
Analyst Ratings
24 analystsRevenue
$105.60M+386.66%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Ugur Sahin
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 7,807
- Beta
- 1.29
- Country
- DE
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 6.82
Financials
Revenue
$105.60M+386.7%Net Income
$-820.80MEBITDA
$-584.70MFree Cash Flow
$-44.80MEPS (diluted)
$-3.24Shares Outstanding (diluted)
253.33M+30.8%Operating Expenses
$748.80MCash & Debt
$9.74BReturn of Capital
$132.08MRevenue by Segment (annual)
$261.60MDividend per Share
$2.11Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $2.76B | $-1.09B | $-4.51 |
| 2024 | $2.75B | $-665.30M | $-2.77 |
| 2023 | $3.82B | $930.30M | $3.87 |
| 2022 | $17.31B | $9.43B | $38.08 |
| 2021 | $18.98B | $10.29B | $43.87 |
| 2020 | $482.30M | $15.20M | $0.06 |
| 2019 | $108.60M | $-179.10M | $-0.85 |
| 2018 | $127.58M | $-48.02M | $-0.21 |
| 2017 | $61.60M | $-85.65M | $-0.38 |
Valuation
BNTXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
30-40.00%Social Signal Score
Mentions (11)
- Newsreuters.com·8d ago·Negative
BioNTech to shutter sites in Germany, Singapore as no buyers emerge German COVID‑19 vaccine maker BioNTech said on Monday it would close sites in Germany and Singapore because it failed to find buyers after pivoting away from pandemic-era manufacturing.
View source ↗ - Newsfool.com·14d ago·Negative
BioNTech Stock Recently Got Downgraded. But Is Wall Street Underestimating Its Cancer Pipeline? BMO Capital Markets downgraded BioNTech and lowered its price target for the stock. The move came after BioNTech reduced its 2027 guidance and experienced a clinical setback.
View source ↗ - Newsfool.com·18d ago·Neutral
BioNTech Threw in the Towel on Its Colorectal Cancer Vaccine Trial. Should Investors Be Worried? BioNTech terminated a Phase 2 study of autogene cevumeran in treating colorectal cancer. The setback raises questions about the mRNA vaccine's prospects in treating pancreatic cancer.
View source ↗ - Newsreuters.com·22d ago·Negative
BioNTech says lung cancer drug candidate prolonged lives in trial BioNTech said on Monday that a late-stage trial showed its drug candidate gotistobart led to a clinically meaningful overall survival benefit in a certain form of lung cancer compared with standard treatment.
View source ↗ - Newsglobenewswire.com·22d ago·Neutral
…of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients MAINZ, Germany, and ROCKVILLE, USA, September 14, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and OncoC4, Inc. (“OncoC4”) today announced the first median overall survival (“OS”) data from the non-pivotal stage 1 of the global randomized PRESERVE-003 Phase 3 clinical trial (NCT05671510) of gotistobart (also known as BNT316 or ONC-392), in patients with squamous non-small lung cancer (“NSCLC”) whose disease …
View source ↗ - Newsfool.com·33d ago·Negative
Is BioNTech Stock a No-Brainer Buy on the Dip? BioNTech has not performed well in recent years, as its COVID-19 portfolio has struggled. However, the company's mRNA platform is looking increasingly valuable.
View source ↗ - Newszacks.com·35d ago·Neutral
BNTX Ends Colorectal Cancer Immunotherapy Study, Stock Down BioNTech discontinues a phase II colorectal cancer study after updated data show an efficacy imbalance, while a pancreatic cancer study continues.
View source ↗ - Newsseekingalpha.com·38d ago·Neutral
…On COMIRNATY Variant Expansion And More BioNTech SE maintains a Strong Buy rating, driven by robust late-stage oncology pipeline momentum and strategic partnerships. BNTX's next-gen anti-CTLA-4 gotistobart and PD-L1xVEGF-A bispecific antibody pumitamig have multiple pivotal trial catalysts, with key data readouts expected at WCLC 2026. COMIRNATY's XFG variant expansion provides near-term revenue, but COVID-19 vaccine sales face competitive and demand headwinds, reflected in lowered 2026 guidance…
View source ↗ - Newsbenzinga.com·38d ago·Neutral
BioNTech Stock Dips After BNT122-01 Trial Termination BioNTech SE (NASDAQ:BNTX) shares are dropping Friday after the company announced it will terminate its Phase 2 clinical trial of autogene cevumeran in resected colorectal cancer. Here's what you should know.
View source ↗ - Newsreuters.com·39d ago·Neutral
BioNTech to terminate mid-stage trial of mRNA cancer vaccine BioNTech SE said on Friday it has decided to terminate the mid-stage trial of its experimental mRNA-based cancer vaccine for patients with a type of colorectal cancer, sending the German firm's U.S.-listed shares down nearly 9%.
View source ↗ - Newsbenzinga.com·47d ago·Neutral
Why Is BioNTech Stock Surging on Wednesday? BioNTech SE (NASDAQ:BNTX) stock is trading higher on Wednesday. Investors are probably reacting to Merck & Co Inc. (NYSE:MRK) and Moderna, Inc. (NASDAQ:MRNA) topline data from individualized cancer therapy for advanced skin cancer.
View source ↗
Earnings
Tue, Nov 3(in 4 weeks)
Consensus estimate $0.84 per share
Typical surprise +26.5% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 4$-3.70 vs $-2.40miss
- Tue, May 5$-2.43 vs $-2.54beat
- Tue, Mar 10$-1.44 vs $-0.22miss
- Mon, Nov 3$-0.14 vs $-1.12beat
- Mon, Aug 4$-1.82 vs $-2.69beat
- Mon, May 5$-1.82 vs $-2.48beat
Estimates and results for BNTX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by BNTX officers and directors.
- Bought
- —
- Sold
- $72.5m
0 trades
22 trades
- Sahin Ugursold
- Sahin Ugursold
- Sahin Ugursold
- Sahin Ugursold
- Sahin Ugursold
- Sahin Ugursold
- Sahin Ugursold
- Sahin Ugursold
49 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Val Hoylehouse · OR04 · disclosed Sep 12, 2025 (36d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Oct 3, 2024 (30d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Sep 11, 2024 (12d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed May 15, 2024 (30d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Apr 7, 2024 (24d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Jan 7, 2024 (31d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Jan 7, 2024 (33d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Jan 7, 2024 (32d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Feb 8, 2022 (19d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.